Biosketch Michael Hudecek, MD · Biosketch Michael Hudecek, MD!! Michael Hudecek studied medicine...

1
Biosketch Michael Hudecek, MD ! Michael Hudecek studied medicine at Leipzig University where he focused his doctoral thesis work under the supervision of Dietger Niederwieser on the role of the minor histocompatibility antigen HA1 in graft versus leukemia reaction. For his postdoctoral studies he joined the lab of Stanley Riddell at the Fred Hutchinson Cancer Research Center in Seattle, USA, where he engineered tumor-reactive Chimeric Antigen Receptor (CAR) T cells for adoptive immunotherapy. He returned in 2012 to Germany as a resident physician to start his own lab at the Julius Maximilians University Medical School in Würzburg. Dr. Hudecek’s research interest encompass (1) the identification of tumor-associated antigens, (2) the engineering of tumor-specific CAR T cells and (3) adoptive immunotherapy with the use of CAR-T cells, tumor-specific T cells and antibodies. Recent publications ! Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 19(12):3153-64 (2013) ! Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti-cancer therapy. Curr Opin Immunol. 24(5):633-9 (2012) ! Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116(22):4532-41 (2010) Center for Pathophysiology, Infectiology and Immunology - Medical University of Vienna

Transcript of Biosketch Michael Hudecek, MD · Biosketch Michael Hudecek, MD!! Michael Hudecek studied medicine...

Page 1: Biosketch Michael Hudecek, MD · Biosketch Michael Hudecek, MD!! Michael Hudecek studied medicine at Leipzig University where he focused his doctoral thesis work under the supervision

BiosketchMichael Hudecek, MD!

!  Michael Hudecek studied medicine at Leipzig University where he focused his doctoral thesis work under the supervision of Dietger Niederwieser on the role of the minor histocompatibility antigen HA1 in graft versus leukemia reaction. For his postdoctoral studies he joined the lab of Stanley Riddell at the Fred Hutchinson Cancer Research Center in Seattle, USA, where he engineered tumor-reactive Chimeric Antigen Receptor (CAR) T cells for adoptive immunotherapy. He returned in 2012 to Germany as a resident physician to start his own lab at the Julius Maximilians University Medical School in Würzburg. Dr. Hudecek’s research interest encompass (1) the identification of tumor-associated antigens, (2) the engineering of tumor-specific CAR T cells and (3) adoptive immunotherapy with the use of CAR-T cells, tumor-specific T cells and antibodies."

!Recent publications!"!  Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC,

Rader C, Riddell SR. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 19(12):3153-64 (2013)!

!  Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti-cancer therapy. Curr Opin Immunol. 24(5):633-9 (2012)!

!  Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116(22):4532-41 (2010)!

Center for Pathophysiology, Infectiology and Immunology - Medical University of Vienna